From: Key characteristics impacting survival of COVID-19 extracorporeal membrane oxygenation
Low (< 20) n/(%) | Intermediate (20–49) n/(%) | High (≥ 50) n/(%) | p | |
---|---|---|---|---|
Total | 96 (14.3) | 329 (48.9) | 248 (36.9) | |
Survivor | 19 (19.8) | 97 (29.5) | 95 (38.3) | 0.0024 |
EOLIA criteria fulfilled | 27 (28.1) | 146 (44.4) | 111 (44.8) | 0.0106 |
SOFA (day 1) | ||||
0–9 | 32 (33.3) | 31 (9.4) | 64 (25.8) | 0.0005 |
9–12 | 20 (20.8) | 91 (27.7) | 21 (8.5) | |
12–15 | 15 (15.6) | 71 (21.5) | 4 (1.6) | |
15–21 | 10 (10.4) | 75 (22.8) | 1 (0.4) | |
Missing | 19 (19.8) | 61 (18.5) | 158 (64.7) | |
Intubation prior to ECMO [days] | ||||
< 5 | 25 (26.0) | 171 (52.0) | 79 (32.9) | 0.0005 |
5–7 | 21 (21.9) | 51 (15.5) | 30 (12.1) | |
≥ 8 | 46 (47.9) | 87 (26.4) | 46 (18.5) | |
No prior | 1 (1.0) | 9 (2.7) | 65 (26.2) | |
Missing | 3 (3.1) | 11 (3.3) | 28 (11.3) | |
Major bleeding or thromboembolic events | 70 (72.9) | 254 (77.2) | 112 (45.2) | < 0.0001 |
Secondary bacterial infection (respiratory tract or bloodstream) | 69 (71.9) | 253 (76.9) | 112 (45.2) | < 0.0001 |
Renal replacement therapy | 64 (66.7) | 208 (63.2) | 119 (48.0) | 0.0002 |